NEEDHAM, Mass., Feb. 5, 2013 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced the pricing of an underwritten public offering of 12,000,000 shares of its common stock, offered at a price to the public of …
Pfizer has decided to terminate a brain cancer vaccine partnership with Celldex Therapeutics ... Investors have been less enthusiastic and the company's stock sank 26.2% to $3.53.
Last year a shrunken CuraGen was acquired by Celldex Therapeutics of Needham ... said it had agreed to buy the company for $375 million in cash and stock, with an additional $350 million available to the sellers if they reach certain …
Celldex Therapeutics (NASDAQ: CLDX) announced the initiation of a Phase 1/2 safety pilot and expansion study …
In a report published Friday, Cantor Fitzgerald reiterated its Buy rating on Celldex Therapeutics (NASDAQ: CLDX), and raised its price target from $13.00 to $16.00. Cantor Fitzgerald noted, “We are raising our price target on shares of …
Celldex (NASDAQ: CLDX) presented positive results from the Company's randomized, double-blind Phase 2 study of RINTEGA (rindopepimut) in patients with EGFRvIII-positive, recurrent glioblastoma at the 2015 American Society of …